U.S. Markets open in 8 hrs 5 mins
  • S&P Futures

    3,672.50
    +8.00 (+0.22%)
     
  • Dow Futures

    29,994.00
    +62.00 (+0.21%)
     
  • Nasdaq Futures

    12,505.00
    +42.75 (+0.34%)
     
  • Russell 2000 Futures

    1,850.80
    +3.60 (+0.19%)
     
  • Crude Oil

    46.47
    +0.83 (+1.82%)
     
  • Gold

    1,844.10
    +3.00 (+0.16%)
     
  • Silver

    24.22
    +0.08 (+0.32%)
     
  • EUR/USD

    1.2160
    +0.0010 (+0.0851%)
     
  • 10-Yr Bond

    0.9200
    0.0000 (0.00%)
     
  • Vix

    21.28
    +0.11 (+0.52%)
     
  • GBP/USD

    1.3457
    +0.0004 (+0.0310%)
     
  • USD/JPY

    103.8700
    +0.0100 (+0.0096%)
     
  • BTC-USD

    19,305.93
    +48.35 (+0.25%)
     
  • CMC Crypto 200

    379.07
    +4.66 (+1.25%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

CLASS ACTION UPDATE for NNOX, RCL and MESO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·4 min read

NEW YORK, NY / ACCESSWIRE / October 13, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NNOX Shareholders Click Here: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-information-request-form?prid=10082&wire=1
RCL Shareholders Click Here: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10082&wire=1
MESO Shareholders Click Here: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10082&wire=1

* ADDITIONAL INFORMATION BELOW *

Nano-X Imaging Ltd. (NASDAQ:NNOX)

NNOX Lawsuit on behalf of: investors who purchased August 21, 2020 - September 15, 2020
Lead Plaintiff Deadline : November 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-information-request-form?prid=10082&wire=1

According to the filed complaint, during the class period, Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Royal Caribbean Cruises Ltd. (NYSE:RCL)

RCL Lawsuit on behalf of: investors who purchased February 4, 2020 - March 17, 2020
Lead Plaintiff Deadline : December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10082&wire=1

According to the filed complaint, during the class period, Royal Caribbean Cruises Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.

Mesoblast Limited (NASDAQ:MESO)

MESO Lawsuit on behalf of: investors who purchased April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline : December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=10082&wire=1

According to the filed complaint, during the class period, Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/610345/CLASS-ACTION-UPDATE-for-NNOX-RCL-and-MESO-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders